Optimax Profit Rises 135% Boosting Plans For Main Board Listing

Optimax Holdings Berhad registered revenue of RM27.65 million for the second quarter ended 30 June 2022 (“Q2FY22”), an increase of 53.35% from RM18.03 million for the corresponding quarter of the preceding year.

Consequently, both its Profit Before Tax and Profit After Tax also showed significant improvement, rising 135.32% and 140.54% to RM7.00 million and RM5.02 million, respectively, from RM2.97 million and RM2.09 million for Q2FY21.

Based on a geographical segmentation, the Company’s Central Peninsular Malaysia operations remained the largest revenue contributor at RM15.48 million or 55.99% of the total revenue for Q2FY22. North Peninsular Malaysia and South Peninsular Malaysia accounted for RM4.90 million and RM6.36 million or 17.73% and 23.01% of the total revenue, respectively, while East Malaysia contributed RM905,000 or 3.27% of the total revenue.

Commenting on the performance, Ms. Sandy Tan, Chief Executive Officer of Optimax, said: “The continued improvement in our Group’s financial results came on the back of the resumption of social and economic activities in Malaysia. With the relaxation of COVID-19 restrictions since the latter part of 2021, we have seen a steady increase in the number of patients going for various eye surgeries and procedures at our clinics, including those who had earlier postponed their refractive and cataract surgeries due to the various movement control orders.

For the six-month period ended 30 June 2022 (“6MFY22”), Optimax posted a revenue of RM50.91 million, representing an increase of 56.54% from RM32.52 million in the six-month period ended 30 June 2021 (“6MFY21”). As such, its PBT and PAT grew 124.16% and 129.95% to RM11.34 million and RM8.05 million, respectively, from RM5.06 million and RM3.50 million in 6MFY21.

“Our strong year-to-date financial performance is well-timed to complement our plan to transfer Optimax listing to the Main Market of Bursa Malaysia Securities from ACE Market” said Sandy

On the outlook for the remainder of the financial year ending 31 December 2022, Sandy said: “We are overall optimistic that the prospects for Optimax would remain favourable, especially with the performance of some of our branches now back at pre-COVID-19 levels. Nevertheless, we remain vigilant of the prevailing risks associated with the resurgence of COVID-19 infection, inflation, and supply chain disruptions, and are ready to respond and mitigate any potential downside.

Previous article“Over the Moon” Mooncake Collection 2022 at Shangri-La KL
Next articleTrade Growth Higher Than Expected MIDF Maintains Growth Forecast

LEAVE A REPLY

Please enter your comment!
Please enter your name here